GH

ANALYST NOTE: GUARDANT HEALTH, INC. (GH) DATE: 2026-06-13 CURRENT PRICE: $131.78

1. Structural Readiness

• State: Context-Only (No structural coil defined in the provided data stream).
• Conservative Entry: —
• Breakout Level: —
• Extension: —

2. Thesis Layer

• Primary Secular Theme: Biotech & GLP-1 → Diagnostics (Tier Direct, High Confidence).
• Thesis Exposure: Guardant Health is a direct beneficiary of the secular shift toward liquid biopsy adoption in precision oncology. The company operates at the intersection of early cancer detection (screening) and advanced cancer management (monitoring and therapy selection).
• Conviction Weighting: The thesis is reinforced by the company's unique position as the only provider with an FDA-approved blood test for primary colorectal cancer screening (Shield) that also meets Medicare coverage requirements. This dual exposure to the high-growth screening market and the established oncology monitoring market creates a structural tailwind that is not merely speculative but grounded in regulatory and reimbursement milestones achieved as of mid-2026.

3. Business Overview

Guardant Health, Inc. is a precision oncology company delivering diagnostic blood tests, comprehensive datasets, and advanced analytical solutions. As of June 2026, the business model is driven by three core pillars:

• Oncology Testing: The company offers Guardant360 Liquid and Guardant360 CDx, the first comprehensive FDA-approved liquid biopsy for therapy selection in solid tumors (NSCLC, colorectal, and breast cancer).
• *Evidence:* Q1 2026 oncology revenue reached $205.0 million, a 36% year-over-year increase driven by volume growth to 86,000 tests (up from 59,000) and improved reimbursement rates (E12).
• Screening (Shield): The Shield test is the first FDA-approved blood test for primary colorectal cancer screening in average-risk adults (45+).
• *Evidence:* Q1 2026 screening revenue surged 633% to $41.6 million, driven by Shield volume increasing to 44,000 tests (up from 9,000) (E11).
• *Management Expectations:* Management raised full-year 2026 revenue guidance to $1.30 billion – $1.32 billion (32–34% growth), with screening revenue expected to reach $186 million – $198 million (E1, E3).
• Monitoring (Reveal): The Guardant Reveal test monitors disease recurrence and therapy response.
• *Evidence:* Reveal volumes grew >100% year-over-year in its first full quarter post-launch, reflecting strong adoption in MRD (Minimal Residual Disease) monitoring (E5).
• *Regulatory Context:* Management has submitted data packages to MolDx for coverage in breast cancer surveillance, immuno-oncology monitoring, and chemotherapy monitoring (E6).

4. Archetype and Conviction

• Archetype: Margin Inflector / Growth Leader.
• *Rationale:* The company is transitioning from a pure growth story to one demonstrating significant operating leverage. The massive expansion in screening revenue (633% QoQ growth in Shield) alongside steady oncology growth (36%) suggests a scaling business model where fixed costs are being absorbed by rapidly expanding volume.
• Valuation Context: The financial spine indicates a path to profitability is being pursued, with forward consensus EPS for FY1 at -2.93 and FY2 at -1.99 (E30). While still negative, the narrowing loss trajectory aligns with the revenue guidance raise.
• Conviction Stack:
• *Thesis Strength:* High. The secular demand for early detection is structural, and Guardant holds the first-mover advantage in Medicare-covered liquid biopsy screening.
• *Evidence Quality:* Strong. The evidence base (E1–E14) provides concrete, quantitative validation of volume growth, revenue acceleration, and regulatory milestones (FDA approval, CMS ADLT status, MolDx submissions).
• *Structural Quality:* The "Margin Inflector" archetype is supported by the 633% revenue jump in the screening segment, which typically carries higher margins than custom oncology testing as volume scales.
• *Setup Readiness:* Low/Unknown. As noted in Section 1, no technical setup (coil) is defined in the current data. The investment case rests entirely on fundamental execution and the realization of management's guidance.
• *Rerating Potential:* Significant. If the company continues to execute on the 32–34% growth guidance and demonstrates a clear path to positive EPS (implied by the FY2 improvement), the market may re-rate the stock from a "growth at any cost" to a "profitable growth" multiple.

5. Invalidation, Strengthening, and Gaps

• What Would Invalidate:
• Failure to meet the raised 2026 revenue guidance of $1.30B–$1.32B.
• Reimbursement setbacks for the Shield test or Reveal test (e.g., MolDx denial or CMS rate cuts).
• Significant slowdown in Shield volume growth (e.g., volume dropping below the 230k–245k annualized run-rate implied by guidance).
• What Would Strengthen:
• Successful MolDx approval for Reveal in additional indications (breast cancer, immuno-oncology).
• Positive interim data from the Vanguard study or SOLAR study confirming high sensitivity/specificity for the Shield MCD test.
• Further narrowing of the loss gap in FY2 earnings.
• Gaps in Evidence:
• Cash Runway: No specific data on cash burn rate or liquidity runway as of June 2026 is provided in the evidence block.
• Competitive Landscape: No specific data on competitor activity or market share shifts is included in the provided evidence.

PRIVATE ANALYST CALL

Judgment: Buy Confidence: high Key evidence: Raised 2026 revenue guidance to $1.30B-$1.32B (32-34% growth); Shield screening revenue up 633% YoY to $41.6M in Q1; Reveal volumes up >100% YoY in first full quarter post-launch; First FDA-approved blood test for primary colorectal screening with Medicare coverage. Key risks: Execution risk on achieving raised guidance; potential reimbursement delays or denials from MolDx or CMS; competitive pressure in the liquid biopsy space; continued negative EPS trajectory despite revenue growth. Sizing hint: Position size should reflect the high conviction in the secular thesis and revenue acceleration, tempered by the lack of a defined technical entry point and the absence of profitability. Expected path: Management expects continued volume expansion in Shield and Reveal to drive revenue growth, with the company moving toward a path of profitability as fixed costs are leveraged across higher volumes. Expected horizon: 12 to 24 months for the thesis to fully play out as guidance is met and profitability metrics improve. Failure mode to watch: A significant miss on the 2026 revenue guidance or a regulatory setback regarding Shield or Reveal coverage.